Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypothalamic-endocrine aspects in Huntington's disease.

Asa Petersén1, Maria Björkqvist

  • 1Neuronal Survival Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, BMC A10, 22184 Lund, Sweden. asa.petersen@med.lu.se

The European Journal of Neuroscience
|August 24, 2006
PubMed
Summary

Huntington's disease (HD) involves brain cell death and hypothalamic dysfunction. Investigating neuroendocrine changes may reveal biomarkers for new Huntington's disease therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease.

Brain pathology (Zurich, Switzerland)·2026
Same author

Analyses of the Effects of Wild-Type TDP-43 Overexpression in Oxytocin Neurons in Mice.

Neuropathology and applied neurobiology·2026
Same author

β-Blocker effects in huntington's disease: A caution on clinical interpretation.

Journal of Huntington's disease·2025
Same author

Differential effects of overexpression of mutant huntingtin and TDP-43 in agouti-related protein neurons in the arcuate nucleus of the hypothalamus in mice.

Acta neuropathologica communications·2025
Same author

Special issue: Glia and non-neuronal cells in Huntington's disease.

Journal of Huntington's disease·2025
Same author

The role of oligodendroglial dysfunction in Huntington's disease.

Journal of Huntington's disease·2025

Area of Science:

  • Neuroscience
  • Genetics
  • Endocrinology

Background:

  • Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by CAG triplet repeat expansion in the huntingtin gene.
  • Neuropathology in HD includes protein aggregates and neuronal loss in the striatum and cerebral cortex.
  • Early HD stages show hypothalamic atrophy, affecting orexin and somatostatin cell populations, potentially explaining symptoms like sleep and weight disturbances.

Purpose of the Study:

  • To explore the role of hypothalamic and endocrine system dysfunction in Huntington's disease.
  • To investigate neuroendocrine changes as potential biomarkers for HD.
  • To identify novel therapeutic targets for Huntington's disease.

Main Methods:

  • Review of neuropathological findings in HD, focusing on the hypothalamus.

Related Experiment Videos

  • Analysis of endocrine changes in HD patients and mouse models.
  • Consideration of neuroendocrine factors in cerebrospinal fluid, blood, and urine as potential biomarkers.

    • Main Results:

    • Hypothalamic atrophy and neuronal loss occur early in HD.
    • HD patients exhibit endocrine alterations, including elevated cortisol, reduced testosterone, and increased diabetes prevalence.
    • HD mouse models show hypothalamic-pituitary-adrenal axis dysfunction and pancreatic beta-cell/adipocyte issues.

    Conclusions:

    • The hypothalamus and endocrine system are significantly impacted in Huntington's disease.
    • Neuroendocrine factors may serve as valuable biomarkers for disease state and therapeutic response in HD.
    • Understanding these neuroendocrine changes could lead to novel therapeutic strategies for Huntington's disease.